Related references
Note: Only part of the references are listed.Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme
B. Zinman et al.
DIABETES OBESITY & METABOLISM (2012)
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2012)
Liraglutide in oral antidiabetic drug combination therapy
A. J. Garber
DIABETES OBESITY & METABOLISM (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
John B. Buse et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Liraglutide in clinical practice: dosing, safety and efficacy
G. E. Peterson et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
Mary Parks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
How Does Treatment Satisfaction Work? Modeling determinants of treatment satisfaction and preference
Mark Peyrot et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes A retrospective cohort study
Rebecca A. Noel et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes
A. Nicolucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study
Robyn Houlden et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Risk factors for renal dysfunction in type 2 diabetes - UK prospective diabetes study 74
Ravi Retnakaran et al.
DIABETES (2006)
Prevalence and control of dyslipidemia among persons with diabetes in the United States
MJ Jacobs et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
SH Saydah et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Patient perceptions of diabetes and diabetes therapy: assessing quality of life
C Bradley et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
CB Juhl et al.
DIABETES (2002)
Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
PM Hellström et al.
PHYSIOLOGY & BEHAVIOR (2001)
Obesity and disease management: Effects of weight loss on comorbid conditions
JW Anderson et al.
OBESITY RESEARCH (2001)